Intellia Therapeutics Reports H1 2026 Profit Guidance of $33.5M–39.5M, Swinging From Prior-Year Loss

According to its announcement, Intellia Therapeutics (stock code: 03696) expects net profit of approximately $33.5 million to $39.5 million for the first half of 2026, compared with a net loss of $19.2 million in the same period of 2025. Revenues for H1 2026 are projected at approximately $103 million to $107 million, representing 2.73x to 2.87x year-over-year growth. Adjusted non-GAAP net profit is estimated at $45.5 million to $51.5 million, versus a net loss of $15.4 million in H1 2025. The company attributed the improvement to increased revenues from licensing, co-development, and research collaboration agreements, combined with operational efficiency gains.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments